These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32648458)

  • 1. Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
    Choi HS; Kim CS; Ma SK; Kim SW; Bae EH
    Ann Palliat Med; 2020 Jul; 9(4):2357-2360. PubMed ID: 32648458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report.
    Kongmalai T; Chuanchaiyakul N; Srinoulprasert Y; Thongtang N
    J Med Case Rep; 2023 Mar; 17(1):89. PubMed ID: 36899379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report.
    Awanami Y; Fukuda M; Nonaka Y; Takashima T; Matsumoto K; Yamasaki M; Miyazono M; Ikeda Y
    BMC Nephrol; 2017 Jul; 18(1):221. PubMed ID: 28683788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?
    Artunc F
    Kidney Int; 2020 Dec; 98(6):1393-1395. PubMed ID: 33276863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome.
    Skeby CK; Hummelgaard S; Gustafsen C; Petrillo F; Frederiksen KP; Olsen D; Kristensen T; Ivarsen P; Madsen P; Christensen EI; Nielsen R; Birn H; Glerup S; Weyer K
    Kidney Int; 2023 Oct; 104(4):754-768. PubMed ID: 37406929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
    Shen H; Feng S; Lu Y; Jiang L; Yang T; Wang Z
    Ren Fail; 2020 Nov; 42(1):405-412. PubMed ID: 32349585
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Podocytes in Mouse Nephrotic Syndrome.
    Suzuki T; Iyoda M; Kanazawa N; Tachibana S; Honda H
    Lab Invest; 2023 Sep; 103(9):100199. PubMed ID: 37331628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
    Haas ME; Levenson AE; Sun X; Liao WH; Rutkowski JM; de Ferranti SD; Schumacher VA; Scherer PE; Salant DJ; Biddinger SB
    Circulation; 2016 Jul; 134(1):61-72. PubMed ID: 27358438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
    Di Bartolo B; Scherer DJ; Brown A; Psaltis PJ; Nicholls SJ
    BioDrugs; 2017 Jun; 31(3):167-174. PubMed ID: 28424973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
    Farnier M
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
    Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
    J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery.
    Akiyama T; Ozaki K; Takano T; Yoneyama S; Kubota N; Okubo T; Ikegami R; Hoyano M; Yanagawa T; Inomata T
    Intern Med; 2023 Nov; 62(22):3361-3365. PubMed ID: 37005262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study.
    Han J; Bilgrami S; Ross S; Broadhead H; Attar N
    Int J Cardiol; 2021 Jan; 322():240-244. PubMed ID: 32827563
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
    Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report.
    Morino J; Hirai K; Kaneko S; Minato S; Yanai K; Mutsuyoshi Y; Ishii H; Matsuyama M; Kitano T; Shindo M; Aomatsu A; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
    Ren Fail; 2020 Nov; 42(1):173-178. PubMed ID: 32046605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.